Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder

Psychiatry Research

Volumn 160, Issue 1, 2008, Pages 72-82

  Herrera Guzmán, Ixchel ^a,b   Gudayol Ferré, Esteve ^a,b   Lira Mandujano, Jennifer ^b   Herrera Abarca, Jorge ^a,c   Herrera Guzmán, Daniel ^a,d   Montoya Pérez, Karina ^b   Guardia Olmos, Joan ^e  

^a Clinica de Enfermedades Crónicas Y de Procedimientos Especiales C E C Y P E   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d Centro Michoacano   (Mexico)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bupropion; Cognitive effects; Depression; Neuropsychological predictors; Neuropsychology

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL FUNCTION; MENTAL PATIENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; TREATMENT RESPONSE; VISUAL MEMORY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRIEF PSYCHIATRIC RATING SCALE; BUPROPION; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PAROXETINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 44649105675     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2007.04.012     Document Type: Article

References (51)

1. Alexopoulos G.S., Kiosses D.N., Heo M., Murphy C.F., Shanmugham B., and Guning-Dixon F. Executive Dysfunction and the course of geriatric depression. Biological Psychiatry 58 (2005) 204-210
2. Airaksinen E., Larsson M.L., Lundberg I., and Forsell Y. Cognitive functions in depressive disorders: evidence from a population based study. Psychological Medicine 34 (2004) 83-91
3. Ascher J.A., Cole J., Colin J., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., and Richeison E. Bupopion: a review of its mechanisms and antidepressant activity. Journal of Clinical Psychiatry 56 (1995) 395-401
4. Ashtari M., Greenwald B.S., Kramer-Ginsberg E., Hu J., Wu H., Patel M., Auperie P., and Pollack S. Hippocampal/amygdala volumes in geriatric depression. Psychological Medicine 29 (1999) 629-639
5. Austin M.P., Mitchell P.M., and Goodwin G.M. Cognitive deficits in depression. British Journal of Psychiatry 178 (2001) 200-206
6. Banachewski R. Non-stimulant medication for ADHD. European Child and Adolescent Psychiatry. Supplement (2004) 102-116
7. Barrickmann L.L., Perry P.J., Allen A.J., Kuperman S., Arndt E.V., Herrmann K.J., and Schumacher E. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34 (1995) 649-657
8. Bremner J.D., Vythilingam M., Vermetten E., Vaccarino V., and Charney D. Deficits in hippocampal and anterior cingulated functioning during verbal declarative memory encoding in midlife major depression. American Journal of Psychiatry 161 (2004) 537-545
9. Campbell S., Marriott M., Nahmias C., and MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. American Journal of Psychiatry 161 (2004) 598-607
10. Cassano G.B., Puca F., Scapicchio P.L., Trabucch M., and for the Italian Study Group on Depression in Elderly Patients. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Journal of Clinical Psychiatry 63 (2002) 396-402
11. Clay T.H., Gualtieri T., Evans R.W., and Gullion M. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacology Bulletin 24 (1988) 143-148
12. Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., and Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depression and Anxiety 21 (2005) 78-89
13. Dong J., and Blier P. Modification of norepinephrine, and serotonin, but not dopamine neuron firing by sustained bupropion treatment. Psychopharmacology 155 (2001) 52-57
14. Dunkin J.J., Leuchter A.F., Cook I.A., Kasl-Godley J.E., Abrams R.N., and Rosenberg-Thompson S. Executive Dysfunction predicts nonresponse to fluoxetine in major depression. Journal of Affective Disorders 60 (2000) 13-23
15. Egeland J., Rund B.O., Sundet K., Landro N.I., Asbjornsen A., Lund A., Rones A., Stordal K.I., and Hughdahl K. Attention profile in schizophrenia compared with depression: differential effects of processing speed, selective attention and vigilance. Acta Psychiatrica Scandinavica 108 (2003) 276-284
16. Evins A.E., Deckersbach T., Cather C., Freudenreich O., Culhane M.A., Henderson D.C., Green M.F., Schoenfeld D.A., Rigotti N.A., and Goff D.C. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Journal of Clinical Psychiatry 66 (2005) 1-7
17. Fava M., Papakostas G.I., Pertersen T., Mahal Y., Quitkin F., Stewart J., and McGrant P. Switching to bupropion in fluoxetine-resistant major depressive disorder. Annals of Clinical Psychiatry 15 (2003) 17-22
18. Fredman S.J., Fava M., Kienke A.S., White C.N., Nieremberg A.A., and Rosenbaum F.J. Partial response, nonresponse and relapse with selective serotonin reuptake inhibitors in major depression: a survey of "next step" practices. Journal of Clinical Psychiatry 61 (2000) 403-408
19. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6 (1967) 278-296
20. Harvey P.O., Le Bastard G., Pochon J.B., Levy R., Allilaire J.F., Dubois B., and Fossati P. Executive functions and updating of the contents of working memory in unipolar depression. Journal of Psychiatric Research 38 (2004) 567-576
21. Hurt R.D., Sachs D.P.L., Glober E.D., Offord K.P., Johnston J.A., Dale L.C., Khayrallah M.A., Scroeder D.R., Glover P.N., Sullivan C., Croghan I.T., and Sullivan P.A. Comparison of sustained release bupropion and placebo for smoking cessation. New England Journal of Medicine 17 (1997) 1195-1202
22. Kampf-Sherf O., Zlotogorski Z., Gilboa A., Speedie L., Lereya J., Rosca P., and Shavit Y. Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. Journal of Affective Disorders 82 (2004) 453-459
23. Koetsier G.C., Volkers A.C., Tulen J.H.M., Passchier J., Van der Broek W., and Bruijn J.A.C.P.T. Performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. Journal of Psychiatric Research 36 (2002) 391-397
24. Lezak M.D., Howiesson D.B., and Loring D.W. Neuropsychological Assessment. Fourth ed. (2004), Oxford University Press
25. Little J.T., Ketter T.A., Dunn R.T., Benson B.E., Willis M.W., Luckenbaugh D.A., and Post R.M. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry 57 (2005) 220-228
26. MacQueen G.L., Campbell S., McEwen B.S., Macdonald K., Amano S., Joffe R.T., Nahmias C., and Young L.T. Course of illness, hippocampal function, and hippocampal volume in major depression. Proceedings of the National Academy of Sciences 100 (2003) 1387-1392
27. Meyer J.H., Goulding V.S., Wilson A.A., Hussey D., Christiensen B.K., and Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163 (2002) 102-105
28. Millan M.J. The role of monoamines in the actions of established and novel antidepressant agents: a critical review. European Journal of Pharmacology 500 (2004) 371-384
29. Moron J.A., Brockington A., Wise R.A., Rocha B.A., and Hope B.T. Dopamine uptake through the norepinephrine transporter I brain regions with low levels of the dopamine transporter: evidence from knockout mouse lines. Journal of Neuroscience 22 (2002) 389-395
30. Nebes R.D., Pollock B.G., Houck P.R., Butters M.A., Mulsant B.H., Zmunda M.D., and Reynolds C.F. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double blind clinical trial with nortriptyline and paroxetine. Journal of Psychiatric Research 37 (2003) 99-108
31. Piacentini M.F., Clinkers R., Meeuse R., Sarre S., Ebinger G., and Michotte Y. Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in rat. Journal of Applied Physiology 95 (2003) 652-656
32. Porter R.J., Gallagher P., Thompson J.M., and Youg A.H. Neurocognitive impairment in drug free patients with major depressive disorder. British Journal of Psychiatry 182 (2001) 214-220
33. Posener J.A., Wang L., Gado M.H., Province M.A., Miller M.I., Babb C.M., and Csernansky J.G. High-dimensional mapping of the hippocampus in depression. American Journal of Psychiatry 60 (2003) 83-89
34. Rao U., Ott G.E., Keh-Ming L., Gerstik L., and Poland R.E. Effects of Bupropion on Nocturnal Urinary Free Cortisol and its Association with Antidepressant Response (2005)
35. Reimherr F.W., Cunningham L.A., Batey S.R., Johnston J.A., and Ascher J.A. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained release bupropion tablets versus placebo in depressed patients. Clinical Therapeutics 20 (1998) 505-516
36. Robbins T.W., James M., Owen A.M., Sahakian B.J., McIness L., and Rabitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5 (1994) 266-281
37. Rogers M., Bradshaw J.L., Pantellis C., and Philips J.G. Frontostriatal deficits in unipolar major depression. Brain Research Bulletin 47 (1998) 297-310
38. Rusch B.D., Abercrombie H.C., Oakes T.R., Schaefer S.M., and Davidson S.J. Hippocampal morphometry in depressed patients and control subjects: relations to anxiety symptoms. Biological Psychiatry 50 (2001) 960-964
39. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weiisstaub N., Lee J., Duman R., Arancio O., Belzung C., and Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
40. Saylam C., Ucerler H., Kitis O., Ozand E., and Gonul A.S. Reduced hippocampal volume in drug-free depressed patients. Surgical Radiological Anatomy 4 (2006) 1-6
41. Sheline Y.I., Wang P.O., Mokhtar H.G., and Csernanky J.G. Hippocampal trophy in recurrent major depression. Proceedings of the National Academy of Sciences 93 (1996) 3908-3913
42. Sheline Y.I., Sanghavi M., Mintun M.A., and Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. The Journal of Neuroscience 19 (1999) 5034-5043
43. Sobin C., and Sackeim H. Psychomotor symptoms of depression. American Journal of Psychiatry 154 (1997) 4-17
44. Stahl S.M., Zhang L., Damatarca C., and Grady M. Brain circuits determine destiny in depression: a novel approach to psychopharmacology of wakefulness, fatigue, and executive dysfunction in Major Depressive Disorder. Journal of Clinical Psychiatry 64 suppl. 11 (2003) 6-17
45. Swainson R., Hodges J.R., Galton C.J., Semple J., Michael A., Dunn B.D., Iddon J.L., Robbins T.W., and Sahakian B. Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dementia and Geriatric Cognitive Disorders 12 (2001) 265-280
46. Taylor B.P., Bruder G.E., Stewart J.W., McGrant P.J., Halperin J., Ehrlichman H., and Quitkin F.M. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed patients. American Journal of Psychiatry 163 (2006) 73-78
47. Thase M.E., and Rush A.J. Treatment-resistant depression. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation Progress (1995), New York Raven Pres 1081-1098
48. Vermetten E., Vythilingam M., Southwick S.M., Charney D.S., and Bremner D.J. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biological Psychiatry 54 (2003) 693-702
49. Videbech P., and Ravnkilde B. Hippocampal volume in depression: a meta-analysis of MRI studies. American Journal of Psychiatry 161 (2004) 1957-1966
50. Weiland-Fielder P., Erickson K., Waldeck T., Luckenbaurg D.A., Pike D., Boone O., Charney D., and Neumeister A. Evidence for continuing neuropsychological impairments in depression. Journal of Affective Disorders 82 (2004) 253-258
51. Zung W.W., Brodie K.H., Fabre L., McLendon D., and Garver D. Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology 79 (1983) 343-347